Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.9K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.9K
Diabetic Nephropathy01:28

Diabetic Nephropathy

2
Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration...
2
Blood and Nerve Supply to the Kidney01:18

Blood and Nerve Supply to the Kidney

6.2K
The kidneys are vital organs responsible for filtering and cleaning blood, removing waste products, and regulating electrolyte levels. To perform these essential functions, they require a constant and robust blood supply.
Bloody Supply to the Kidneys:
The kidneys receive their blood supply from the renal arteries, which branch off from the abdominal aorta—the main artery supplying the abdomen and lower body. The renal arteries enter the kidneys at the hilum, a notch on the medial side of...
6.2K
Imaging Studies VII: Vascular Imaging01:19

Imaging Studies VII: Vascular Imaging

528
DefinitionRenal angiography, also known as renal arteriography, is an imaging technique used to obtain a comprehensive view of blood flow and the vascular structure of blood vessels in the kidneys and surrounding areas.PurposeRenal angiography detects blood vessel abnormalities in the kidneys, such as aneurysms, stenosis, thrombosis, vascular tumors, and renal artery stenosis. It evaluates kidney function and guides interventional treatments like angioplasty or stent placement.Pre-Procedure...
528
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.2K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Direct His/LBB pacing as an alternative to biventricular pacing in patients with HFrEF and a typical LBBB: Design and rationale for the His-Alternative II trial.

American heart journal·2026
Same author

Prevalence and types of anxiety disorders among patients with cardiac conditions and elevated HADS-A scores: findings from the initial screening phase of the Heart and Mind trial in Denmark.

BMJ open·2026
Same author

Artificial intelligence-enhanced wearable technology enables ventricular arrhythmia prediction.

European heart journal. Digital health·2026
Same author

Prevalence of deleterious variants in cardiomyopathy genes in early-onset atrial fibrillation.

European journal of human genetics : EJHG·2026
Same author

Lipoprotein(a), interleukin-6 and cardiovascular risk in a primary prevention setting.

Atherosclerosis·2026
Same author

His Pacing vs Biventricular Pacing for Cardiac Resynchronization Therapy: Long-Term Follow-Up From the His-Alternative I Trial.

JACC. Clinical electrophysiology·2026

Related Experiment Video

Updated: Apr 17, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.5K

Renal denervation.

Lene Kjær Olsen1, Anne-Lise Kamper1, Jesper Hastrup Svendsen2

  • 1Department of Nephrology, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.

European Journal of Internal Medicine
|February 14, 2015
PubMed
Summary
This summary is machine-generated.

Renal denervation (RDN) shows mixed results for resistant hypertension. While early studies indicated significant blood pressure reduction, recent trials question its effectiveness, necessitating further research for patient selection and long-term outcomes.

Keywords:
Antihypertensive treatmentBlood pressureRenal denervationResistant hypertension

More Related Videos

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

892
Quantifying Acute Changes in Renal Sympathetic Nerve Activity in Response to Central Nervous System Manipulations in Anesthetized Rats
06:30

Quantifying Acute Changes in Renal Sympathetic Nerve Activity in Response to Central Nervous System Manipulations in Anesthetized Rats

Published on: September 11, 2018

8.4K

Related Experiment Videos

Last Updated: Apr 17, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

4.5K
Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

892
Quantifying Acute Changes in Renal Sympathetic Nerve Activity in Response to Central Nervous System Manipulations in Anesthetized Rats
06:30

Quantifying Acute Changes in Renal Sympathetic Nerve Activity in Response to Central Nervous System Manipulations in Anesthetized Rats

Published on: September 11, 2018

8.4K

Area of Science:

  • Cardiovascular Medicine
  • Interventional Cardiology
  • Nephrology

Background:

  • Resistant hypertension poses a significant clinical challenge.
  • Renal denervation (RDN) emerged as a potential therapeutic option.
  • The sympathetic nervous system plays a key role in blood pressure regulation.

Purpose of the Study:

  • To review current knowledge on RDN for resistant hypertension.
  • To summarize findings from key clinical trials.
  • To identify limitations and unanswered questions regarding RDN efficacy and application.

Main Methods:

  • Review of published literature on RDN.
  • Analysis of results from landmark studies like Symplicity HTN-1, HTN-2, and HTN-3.
  • Examination of registry data and expert recommendations.

Main Results:

  • Early studies (HTN-1, HTN-2) demonstrated feasibility and significant blood pressure (BP) reduction with RDN.
  • The Symplicity HTN-3 trial showed similar BP reductions in RDN and sham-control groups.
  • Large-scale registry data continues to suggest a favorable BP-lowering effect of RDN.

Conclusions:

  • Recent controlled studies cast doubt on the BP-lowering efficacy of RDN.
  • RDN should currently be limited to clinical studies.
  • Further research is needed to define patient selection criteria, optimize techniques, and assess long-term cardiovascular outcomes.